Boston Scientific, Watchman FLX

Boston Scientific’s Watchman could be new option for patients post ablation: study
The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent cardiac ablation for AFib.
Boston Scientific Watchman FLX demonstrates superiority to anticoagulants in study
Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.
Boston Sci stock climbs 5% on positive Watchman FLX data
Boston Scientific (BSX) stock climbed 5% after a study showed its Watchman FLX device was superior to oral anti-coagulants in reducing bleeding risks following cardiac ablation.
Boston Scientific resumes Farapulse pulsed field ablation study in first-line afib
Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy. | Boston Scientific aims to see whether its Farapulse platform can deliver results for patients with atrial fibrillation before they take any anti-arrhythmic medications.
Boston Scientific resumes study of pulse field ablation as first-line AFib therapy
Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial fibrillation (AFib).
Promising OPTION Trial Results Justify Buy Rating for Boston Scientific’s Watchman Device
Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Larry
medtechdive2d
The PFA race is heating up. Here’s where the market stands after J&J’s approval.
Boston Scientific, Medtronic and J&J are moving quickly to secure their place in the fast-growing pulsed field ablation space ...
FierceBiotech1d
AHA 2024: Boston Scientific, Abbott tout long-term heart occluder data
Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...
GlobalData on MSN2d
Boston Scientific reports outcomes from trial of LAAC device
The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.
Medtronic races for market share in fast-growing treatment for AFib
With supplier issue now resolved, the Minnesota-run medtech company expects to “reach and then exceed” market growth in the ...
clinicaltrialsarena9d
Boston Scientific resumes enrolment in pulsed field ablation trial
Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...
Benzinga.com2d
Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?
for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented at ...
BSX : WATCHMAN FLX Device Reduces Bleeding Risk, Matches Stroke Prevention After Cardiac Ablation
Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...